NORD Refines Orphan Exclusivity Position
This article was originally published in The Pink Sheet Daily
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.
You may also be interested in...
Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score
The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry
With so many Democratic sponsors, Eshoo appears to need to pick up only nine of the 11 undeclared Republicans in order to pass her brand-friendly legislation.
Organization tells Rep. Waxman it still "wholeheartedly" supports his bill, but is planning its legislative approach around longer brand exclusivity.